{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:54:24Z","timestamp":1793120064151,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.jhep.2017.10.027","type":"journal-article","created":{"date-parts":[[2017,12,11]],"date-time":"2017-12-11T14:03:29Z","timestamp":1513001009000},"page":"431-440","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":194,"title":["Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B"],"prefix":"10.1016","volume":"68","author":[{"given":"Harry L.A.","family":"Janssen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizia R.","family":"Brunetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Jun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Massetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anh-Hoa","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adarsh","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacky","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey H.","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuj","family":"Gaggar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Mani","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hoon","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoky C.S.","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward J.","family":"Gane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2017.10.027_b0005","unstructured":"Razavi-Shearer-Spink D. Global Estimate of Hepatitis B and Hepatitis Delta. Polaris Observatory 2016;http:\/\/www.polarisobservatory.com\/."},{"key":"10.1016\/j.jhep.2017.10.027_b0010","unstructured":"World Health Organization. Draft global health sector strategies: Viral hepatitis, 2016\u20132021. SIXTY-NINTH WORLD HEALTH ASSEMBLY. http:\/\/apps.who.int\/gb\/ebwha\/pdf_files\/WHA69\/A69_32-en.pdf?ua=1; 2016."},{"key":"10.1016\/j.jhep.2017.10.027_b0015","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1136\/gutjnl-2011-301073","article-title":"Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection","volume":"61","author":"Bertoletti","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2017.10.027_b0020","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jhep.2009.12.017","article-title":"The molecular basis of the failed immune response in chronic HBV: therapeutic implications","volume":"52","author":"Maini","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.10.027_b0025","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(14)61682-2","article-title":"GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"385","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2017.10.027_b0030","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1158\/1055-9965.EPI-15-0578","article-title":"Global cancer incidence and mortality rates and trends\u2013an update","volume":"25","author":"Torre","year":"2016","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.jhep.2017.10.027_b0035","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.10.027_b0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hep Intl"},{"key":"10.1016\/j.jhep.2017.10.027_b0045","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","article-title":"Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013","volume":"386","author":"Schweitzer","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2017.10.027_b0050","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.10.027_b0055","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/ni1303","article-title":"Innate immune recognition of viral infection","volume":"7","author":"Kawai","year":"2006","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jhep.2017.10.027_b0060","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.4049\/jimmunol.1300787","article-title":"Targeting uptake receptors on human plasmacytoid dendritic cells triggers antigen cross-presentation and robust type I IFN secretion","volume":"191","author":"Tel","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.jhep.2017.10.027_b0065","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.4049\/jimmunol.174.7.4043","article-title":"Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN","volume":"174","author":"Bekeredjian-Ding","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.jhep.2017.10.027_b0070","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1471-2172-9-39","article-title":"Comparison of human B cell activation by TLR7 and TLR9 agonists","volume":"9","author":"Hanten","year":"2008","journal-title":"BMC Immunol"},{"key":"10.1016\/j.jhep.2017.10.027_b0075","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jhep.2015.02.048","article-title":"Liver-directed gene therapy of chronic hepadnavirus infection using interferon alpha tethered to apolipoprotein A-I","volume":"63","author":"Berraondo","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.10.027_b0080","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1124\/jpet.113.207878","article-title":"Pharmacokinetic and pharmacodynamic properties of GS-9620, a novel Toll-like receptor 7 agonist, demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses","volume":"348","author":"Fosdick","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jhep.2017.10.027_b0085","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1053\/j.gastro.2013.02.003","article-title":"GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees","volume":"144","author":"Lanford","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.10.027_b0090","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jhep.2014.12.026","article-title":"Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B","volume":"62","author":"Menne","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.10.027_b0095","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jhep.2015.02.037","article-title":"The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection","volume":"63","author":"Gane","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.10.027_b0100","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3851\/IMP2845","article-title":"Safety, pharmacokinetics and pharmacodynamics of the oral toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis C","volume":"20","author":"Lawitz","year":"2015","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2017.10.027_b0105","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1517\/14740338.2011.555079","article-title":"Safety and efficacy of treatment for chronic hepatitis C with a focus on pegylated interferons: the backbone of therapy today and in the future","volume":"10","author":"Ferenci","year":"2011","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jhep.2017.10.027_b0110","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3851\/IMP2548","article-title":"Safety, pharmacokinetics and pharmacodynamics of GS-9620, an oral Toll-like receptor 7 agonist","volume":"18","author":"Lopatin","year":"2013","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2017.10.027_b0115","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1517\/14712598.2011.552906","article-title":"Interferon in the treatment of chronic hepatitis C: a drug caught between past and future","volume":"11","author":"Vezali","year":"2011","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.jhep.2017.10.027_b0120","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2893.2008.01037.x","article-title":"Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B","volume":"16","author":"Chan","year":"2009","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2017.10.027_b0125","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.immuni.2014.05.004","article-title":"Type I interferon protects antiviral CD8+ T cells from NK cell cytotoxicity","volume":"40","author":"Xu","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.jhep.2017.10.027_b0130","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.immuni.2014.05.003","article-title":"Type I interferons protect T cells against NK cell attack mediated by the activating receptor NCR1","volume":"40","author":"Crouse","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.jhep.2017.10.027_b0135","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/hep.22744","article-title":"Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients","volume":"49","author":"Moucari","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.10.027_b0140","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/cid\/cis859","article-title":"Close monitoring of hepatitis B surface antigen levels helps classify flares during peginterferon therapy and predicts treatment response","volume":"56","author":"Sonneveld","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2017.10.027_b0145","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/hep.22760","article-title":"Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B","volume":"49","author":"Brunetto","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.10.027_b0150","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1053\/j.gastro.2015.09.043","article-title":"Combination of tenofovir disoproxil fumarate and peginterferon alpha-2a increases loss of hepatitis b surface antigen in patients with chronic hepatitis B","volume":"150","author":"Marcellin","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.10.027_b0155","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1089\/jir.2013.0064","article-title":"Emerging roles for immunomodulatory functions of free ISG15","volume":"33","author":"Campbell","year":"2013","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.jhep.2017.10.027_b0160","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.4049\/jimmunol.176.9.5205","article-title":"Regulation of intestinal dendritic cell migration and activation by plasmacytoid dendritic cells, TNF-alpha and type 1 IFNs after feeding a TLR7\/8 ligand","volume":"176","author":"Yrlid","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.jhep.2017.10.027_b0165","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/1471-2334-7-120","article-title":"Evaluation of immune response to Hepatitis B vaccine in health care workers at a tertiary care hospital in Pakistan: an observational prospective study","volume":"7","author":"Zeeshan","year":"2007","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jhep.2017.10.027_b0170","unstructured":"Hamborsky J KA, Wolfe S, (eds). Epidemiology and Prevention of Vaccine-Preventable Diseases 13th. ed. Centers for Disease Control and Prevention 2015;10:149\u2013175."},{"key":"10.1016\/j.jhep.2017.10.027_b0175","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.4049\/jimmunol.1103139","article-title":"IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection","volume":"189","author":"Das","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.jhep.2017.10.027_b0180","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1042\/CS20160069","article-title":"IL-10-producing regulatory B-cells suppressed effector T-cells but enhanced regulatory T-cells in chronic HBV infection","volume":"130","author":"Liu","year":"2016","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.jhep.2017.10.027_b0185","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1046\/j.1365-2443.2002.00515.x","article-title":"Requirement of the IFN-alpha\/beta-induced CXCR3 chemokine signalling for CD8+ T cell activation","volume":"7","author":"Ogasawara","year":"2002","journal-title":"Genes Cells"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882781732408X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882781732408X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,25]],"date-time":"2018-08-25T09:54:17Z","timestamp":1535190857000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016882781732408X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S016882781732408X"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2017.10.027","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2017.10.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}